You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
阿斯利康藥廠季度轉虧 料新冠疫苗銷售跌逾兩成
阿思達克 02-10 17:05
英國新冠疫苗生產商阿斯利康(AstraZeneca)公佈去年第四季業績。季度稅後虧損3.46億美元,對上年度同期稅後溢利10.05億美元。每股季度虧損22美仙,經調整後爲溢利1.67美元。季度收益120.11億美元,按年升62%。但研發成本及銷售與行政成本分別按年升50%及59%,導致經營溢利由正轉負。 公司新冠疫苗季度銷售17.62億美元,全年銷售39.81億美元。公司預期今年新冠疫苗銷售按年跌逾兩成,且毛利率會低於公司產品平均。但大部分銷售減少將由抗體藥Evusheld銷售增長抵銷。公司預期今年收入將錄高雙位數增長。公司去年銷售按年升38%至374.17億美元,市場預期公司今年銷售額爲427.3億美元。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account